N-(2-Aminoethyl)-2-methylpyrrolidin | 35025-84-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: N-(2-Aminoethyl)-2-methylpyrrolidin
• 英文别名: 2-(2-methyl-pyrrolidin-1-yl)-ethylamine；2-(2-methyl-pyrrolidino)-ethylamine；2-(2-Methyl-pyrrolidino)-aethylamin；2-(2-Methylpyrrolidin-1-yl)ethan-1-amine；2-(2-methylpyrrolidin-1-yl)ethanamine
• CAS: 35025-84-4
• 化学式: C₇H₁₆N₂
• 分子量: 128.217
• InChiKey: CWCJURPRDOORGY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  5-羟基-2-戊酮 、 N-(2-甲酰胺基乙基)甲酰胺 在 镍 作用下， 生成 N-(2-Aminoethyl)-2-methylpyrrolidin
  参考文献：
  名称：

  Terentew et al., Zhurnal Obshchei Khimii, 1958, vol. 28, p. 1516,1517;engl.Ausg.S.1566,1567

  摘要：

  DOI：

文献信息

• Mild reduction with silanes and reductive amination of levulinic acid using a simple manganese catalyst
  作者：Diego A. Roa、Juventino J. Garcia

  DOI：10.1016/j.ica.2020.120167

  日期：2021.2

  complex [Mn(CO)5Br] was studied for the selective reduction of levulinic acid (LA) to 2-methyl-tetrahydrofuran (MTHF). We further studied the production of pyrrolidines via its reductive amination using silanes (phenylsilane and tetramethyldisiloxane). The results showed high efficiency and selectivity for this reaction leading to high yields using mild reaction conditions.

  摘要研究了使用市售配合物[Mn（CO）5Br]的锰基催化体系将乙酰丙酸（LA）选择性还原为2-甲基-四氢呋喃（MTHF）的方法。我们进一步研究了使用硅烷（苯基硅烷和四甲基二硅氧烷）的还原胺化反应制备吡咯烷的方法。结果表明，在温和的反应条件下，该反应具有很高的效率和选择性，从而导致高收率。
• DIAMINE DERIVATIVE
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP1847530A1

  公开（公告）日：2007-10-24

  The present invention provides a diamine derivative or the like represented by the general formula (I): wherein Q represents an oxygen atom or the like, RG represents a hydrogen atom or the like, RI represents (wherein p and r may be the same or different, and each represents 0 or the like, RA represents a hydrogen atom or the like, and RB and Rc may be the same or different, and each represents a hydrogen atom or the like), RH represents a hydrogen atom or the like, and RJ represents: (wherein q and s may be the same or different, and each represents 0 or the like, RD represents a hydrogen atom or the like, and RE and RF may be the same or different, and each represents a hydrogen atom or the like) or the like}, etc.

  本发明提供了一种二胺衍生物等，由通式(I)表示：其中Q表示氧原子等，RG表示氢原子等，RI表示（其中p和r可以相同或不同，各自表示0或等，RA表示氢原子等，RB和RC可以相同或不同，各自表示氢原子等），RH表示氢原子等，RJ表示：（其中q和s可以相同或不同，各自表示0或等，RD表示氢原子等，RE和RF可以相同或不同，各自表示氢原子等）等}，等等。
• [EN] 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES<br/>[FR] DERIVES AMIDES DE L'ACIDE CARBOXYLIQUE DE 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE 3 ET COMPOSES ASSOCIES EN TANT QU'ANTAGONISTES DE RECEPTEUR DE B1 DE LA BRADYKININE POUR LE TRAITEMENT DE MALADIES INFLAMMATOIRES
  申请人：ELAN PHARM INC

  公开号：WO2004098589A1

  公开（公告）日：2004-11-18

  Disclosed are compounds of formula I and II that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.

  公开的是化合物I和II的结构式，它们是激肽酶B1受体拮抗剂，适用于治疗哺乳动物中由激肽酶B1受体介导的疾病，或缓解与疾病状况相关的不良症状。其中某些化合物表现出增强的效力，并且预计还将表现出延长作用的特性。
• Novel compounds useful for bradykinin B1 receptor antagonism
  申请人：Ye Michael Xiaocong

  公开号：US20070032475A1

  公开（公告）日：2007-02-08

  Disclosed are compounds that are bradykinin B 1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B 1 receptor.

  揭示了一种化合物，它们是布雷金肽B1受体拮抗剂，可用于治疗或缓解由布雷金肽B1受体介导的哺乳动物疾病，或与疾病状况相关的不良症状。
• Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists
  申请人：Tung S. Jay

  公开号：US20050020659A1

  公开（公告）日：2005-01-27

  Disclosed are compounds that are bradykinin B 1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B 1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.

  本发明公开了一种布雷肯肽B1受体拮抗剂化合物，可用于治疗哺乳动物中由布雷肯肽B1受体介导的疾病或缓解与疾病状况相关的不良症状。其中某些化合物表现出增强的效力，并且预计也会表现出增强的作用持续时间。